Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis ...Middle East

The announcement follows the recent IND clearance for KYV-101 to be used in Kyverna's KYSA-7 Phase 2 open-label, multicenter study KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases EMERYVILLE, Calif., Jan. 19, 2024...

Hence then, the article about kyverna therapeutics granted fda fast track designation for kyv 101 in the treatment of patients with refractory progressive multiple sclerosis was published today ( Friday 19/01/2024 - 04:16 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis )

Also on site :

• Marjorie Taylor Greene: UFC fights don't belong on White House lawn
• 1981 Arena Rock Classic, Ranked Among 'Greatest Songs of the '80s,' Became an Instantly Recognizable Party Anthem
• UFC Freedom 250 Topuria vs. Gaethje: horarios, cartelera y transmisión del evento desde la Casa Blanca en Washington